ASGR1 and hepatocellular carcinoma: In summary, four types of self-assembled chitosan nanoparticles Gly-CS-VE, Gal-Gly-CS-VE, Gly-CS-DCA, and Gal-Gly-CS-DCA were successfully fabricated to load DOX for HCC therapy, where the galactosylated Gal-Gly-CS-VE and Gal-Gly-CS-DCA nanoparticles could selectively target to liver via recognizing ASGPR.